Lebrikizumab – Inflammatory/Dermatology Research Grants
Lilly Immunology is committed to improving the lives of individuals living with immunological diseases and disorders. We are driven to developing innovative solutions through our broad portfolio of therapeutic agents directed at multiple targets in cytokine pathways. Through internal research programs and support of investigator initiated studies, we are dedicated to long-term partnerships that will enable us to make a real impact on individuals’ lives. Lilly is also committed to support external research in Dermatological clinical and molecular aspects affecting patients with skin of color.
We are most likely to support external research in these key areas:
- AD in special locations
- Basic research on IL-13 in AD
- Short and long-term real-world trials/cases with lebrikizumab
- Use of lebrikizumab in diverse populations
- Chronic hand eczema
- Studies that support IL-13 role in inflammatory diseases
Lilly will not support external research within its IIR program in the following areas:
- Research questions and therapeutic indications of lebrikizumab that either have been previously investigated and terminated (IPF, COPD, Hodgkin’s lymphoma, asthma) or are being currently investigated (visit clinicaltrials.gov for most updated information)
- Research with a safety primary objective
- Compassionate programs or drug access requests based on humanitarian needs
PIRA™ proposals are AI generated and are not reviewed or endorsed by the sponsoring company.
Title: IL-13 Signaling and Barrier Dysfunction: Mechanistic Insights from Skin and Blood Biomarkers in Patients Treated with Lebrikizumab for Atopic Dermatitis
Rationale: IL-13 is central to epidermal barrier disruption, keratinocyte differentiation, and immune activation in AD. Investigating IL-13 and downstream mediators pre- and post-lebrikizumab can elucidate mechanistic pathways and identify predictive biomarkers of response.
Objectives:
Characterize IL-13–related gene and protein signatures (IL-13Rα1, IL-4Rα, CLDN1, TSLP).
Correlate changes with EASI and pruritus improvements.
Identify biomarkers predictive of clinical response or resistance.
Design Summary:
Translational, single-arm study (N = 30); baseline and Week 16 lesional/non-lesional biopsies and serum cytokine profiling.
Value to Lilly:
Supports Lilly’s mechanistic positioning of IL-13 blockade; enhances biomarker strategy and precision-medicine potential.